Literature DB >> 11207315

HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease.

G Lombardi1, C Germain, J Uren, M T Fiorillo, R M du Bois, W Jones-Williams, C Saltini, R Sorrentino, R Lechler.   

Abstract

Occupational exposure to small molecules, such as metals, is frequently associated with hypersensitivity reactions. Chronic beryllium (Be) disease (CBD) is a multisystem granulomatous disease that primarily affects the lung, and occurs in approximately 3% of individuals exposed to this element. Immunogenetic studies have demonstrated a strong association between CBD and possession of alleles of HLA-DP containing glutamic acid (Glu) at position 69 in the HLA-DP beta-chain. T cell clones were raised from three patients with CBD in whom exposure occurred 10 and 30 years previously. Of 25 Be-specific clones that were obtained, all were restricted by HLA-DP alleles with Glu at DP beta69. Furthermore, the proliferative responses of the clones were absolutely dependent upon DP beta Glu(69) in that a single amino acid substitution at this position abolished the response. As befits a disease whose pathogenesis involves a delayed type hypersensitivity response, the large majority of Be-specific clones secreted IFN-gamma (Th1) and little or no IL-4 (Th2) cytokines. This study provides insights into the molecular basis of DP2-associated susceptibility to CBD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207315     DOI: 10.4049/jimmunol.166.5.3549

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

2.  Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response.

Authors:  Andrew P Fontenot; Brent E Palmer; Andrew K Sullivan; Fenneke G Joslin; Cara C Wilson; Lisa A Maier; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

3.  Conference summary.

Authors:  Philippa Marrack
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

4.  Crystal structure of HLA-DP2 and implications for chronic beryllium disease.

Authors:  Shaodong Dai; Guinevere A Murphy; Frances Crawford; Douglas G Mack; Michael T Falta; Philippa Marrack; John W Kappler; Andrew P Fontenot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-31       Impact factor: 11.205

Review 5.  Linking genetic susceptibility and T cell activation in beryllium-induced disease.

Authors:  Michael T Falta; Natalie A Bowerman; Shaodong Dai; John W Kappler; Andrew P Fontenot
Journal:  Proc Am Thorac Soc       Date:  2010-05

6.  Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease.

Authors:  Andrew P Fontenot; Scott J Canavera; Laia Gharavi; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

7.  Identification of multiple public TCR repertoires in chronic beryllium disease.

Authors:  Natalie A Bowerman; Michael T Falta; Douglas G Mack; Fabian Wehrmann; Frances Crawford; Margaret M Mroz; Lisa A Maier; John W Kappler; Andrew P Fontenot
Journal:  J Immunol       Date:  2014-04-09       Impact factor: 5.422

Review 8.  Immunologic Effects of Beryllium Exposure.

Authors:  Andrew P Fontenot
Journal:  Ann Am Thorac Soc       Date:  2018-04

9.  Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease.

Authors:  Karoline I Gaede; Massimo Amicosante; Manfred Schürmann; Elisabeth Fireman; Cesare Saltini; Joachim Müller-Quernheim
Journal:  J Mol Med (Berl)       Date:  2005-03-05       Impact factor: 4.599

10.  The uses and adverse effects of beryllium on health.

Authors:  Ross G Cooper; Adrian P Harrison
Journal:  Indian J Occup Environ Med       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.